[go: up one dir, main page]

FR2894145B1 - Utilisation de facteur h du complement a titre de medicament - Google Patents

Utilisation de facteur h du complement a titre de medicament

Info

Publication number
FR2894145B1
FR2894145B1 FR0512404A FR0512404A FR2894145B1 FR 2894145 B1 FR2894145 B1 FR 2894145B1 FR 0512404 A FR0512404 A FR 0512404A FR 0512404 A FR0512404 A FR 0512404A FR 2894145 B1 FR2894145 B1 FR 2894145B1
Authority
FR
France
Prior art keywords
complement
factor
medicinal product
medicinal
product
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0512404A
Other languages
English (en)
Other versions
FR2894145A1 (fr
Inventor
Bernadette Cauvin
Frederic Dhainaut
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LFB SA
Original Assignee
LFB SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0512404A priority Critical patent/FR2894145B1/fr
Application filed by LFB SA filed Critical LFB SA
Priority to BRPI0619728-0A priority patent/BRPI0619728A2/pt
Priority to CN2012101497188A priority patent/CN102988958A/zh
Priority to KR1020087016073A priority patent/KR20080091441A/ko
Priority to CA002633102A priority patent/CA2633102A1/fr
Priority to CNA2006800521939A priority patent/CN101336111A/zh
Priority to PCT/FR2006/002693 priority patent/WO2007066017A2/fr
Priority to AU2006323849A priority patent/AU2006323849B2/en
Priority to JP2008543870A priority patent/JP2009518368A/ja
Priority to EP06841898A priority patent/EP1962885A2/fr
Priority to US12/095,949 priority patent/US20080318841A1/en
Publication of FR2894145A1 publication Critical patent/FR2894145A1/fr
Priority to IL191931A priority patent/IL191931A0/en
Application granted granted Critical
Publication of FR2894145B1 publication Critical patent/FR2894145B1/fr
Priority to JP2012168827A priority patent/JP2012211189A/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
FR0512404A 2005-12-07 2005-12-07 Utilisation de facteur h du complement a titre de medicament Expired - Fee Related FR2894145B1 (fr)

Priority Applications (13)

Application Number Priority Date Filing Date Title
FR0512404A FR2894145B1 (fr) 2005-12-07 2005-12-07 Utilisation de facteur h du complement a titre de medicament
US12/095,949 US20080318841A1 (en) 2005-12-07 2006-12-07 Method For Preparing a Factor H Concentrate and the Use Thereof in the Form of a Drug
KR1020087016073A KR20080091441A (ko) 2005-12-07 2006-12-07 인자 ｈ 농축물의 제조방법 및 약물의 형태로서의 그의용도
CA002633102A CA2633102A1 (fr) 2005-12-07 2006-12-07 Procede de preparation d'un concentre de facteur h et utilisation de ce concentre de facteur h au titre de medicament
CNA2006800521939A CN101336111A (zh) 2005-12-07 2006-12-07 制备h因子浓缩物的方法及其药物用途
PCT/FR2006/002693 WO2007066017A2 (fr) 2005-12-07 2006-12-07 Procede de preparation d'un concentre de facteur h et utilisation de ce concentre de facteur h au titre de medicament
BRPI0619728-0A BRPI0619728A2 (pt) 2005-12-07 2006-12-07 método de preparação de um concentrado de fator h e utilização deste concentrado de fator h a tìtulo de medicamento
JP2008543870A JP2009518368A (ja) 2005-12-07 2006-12-07 因子ｈ濃縮物の調製方法及び薬剤の形でのその使用
EP06841898A EP1962885A2 (fr) 2005-12-07 2006-12-07 Procede de preparation d'un concentre de facteur h et utilisation de ce concentre de facteur h au titre de medicament
CN2012101497188A CN102988958A (zh) 2005-12-07 2006-12-07 制备h因子浓缩物的方法及其药物形式的用途
AU2006323849A AU2006323849B2 (en) 2005-12-07 2006-12-07 Method for preparing a factor H concentrate and the use thereof in the form of a drug
IL191931A IL191931A0 (en) 2005-12-07 2008-06-03 Method for preparing a factor h concentrate and the use thereof in the form of a drug
JP2012168827A JP2012211189A (ja) 2005-12-07 2012-07-30 因子ｈ濃縮物の薬剤の形での使用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0512404A FR2894145B1 (fr) 2005-12-07 2005-12-07 Utilisation de facteur h du complement a titre de medicament

Publications (2)

Publication Number Publication Date
FR2894145A1 FR2894145A1 (fr) 2007-06-08
FR2894145B1 true FR2894145B1 (fr) 2008-10-17

Family

ID=36928796

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0512404A Expired - Fee Related FR2894145B1 (fr) 2005-12-07 2005-12-07 Utilisation de facteur h du complement a titre de medicament

Country Status (11)

Country Link
US (1) US20080318841A1 (fr)
EP (1) EP1962885A2 (fr)
JP (2) JP2009518368A (fr)
KR (1) KR20080091441A (fr)
CN (2) CN102988958A (fr)
AU (1) AU2006323849B2 (fr)
BR (1) BRPI0619728A2 (fr)
CA (1) CA2633102A1 (fr)
FR (1) FR2894145B1 (fr)
IL (1) IL191931A0 (fr)
WO (1) WO2007066017A2 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007038995A1 (fr) 2005-09-19 2007-04-12 Csl Behring Gmbh Facteur h pour le traitement de néphropathies chroniques et sa production
FR2933496B1 (fr) * 2008-07-02 2012-10-05 Lfb Biotechnologies Procede de mesure du taux de facteur vii active dans un echantillon
CN109045296A (zh) * 2008-11-10 2018-12-21 阿雷克森制药公司 用于治疗补体相关障碍的方法和组合物
GB0904427D0 (en) 2009-03-13 2009-04-29 Lachmann Peter Treatment of diseases related to hyperactivity of the complement system
AT514675B1 (de) * 2009-07-23 2019-05-15 Baxalta Inc Herstellung von faktor h (fh) und fh-derivaten aus plasma
FR2952640B1 (fr) * 2009-11-16 2012-12-07 Lab Francais Du Fractionnement Procede de fabrication d'une preparation de facteur h
FR2952539B1 (fr) 2009-11-16 2012-01-13 Lab Francais Du Fractionnement Preparation d'un concentre de facteur h
EP2533797A1 (fr) 2010-02-12 2012-12-19 CeMM Forschungszentrum für Molekulare Medizin GmbH Facteur h du complément pour états pathologiques de stress oxydatif
US8796430B2 (en) 2010-05-26 2014-08-05 Baxter International Inc. Method to produce an immunoglobulin preparation with improved yield
AU2010202125B1 (en) 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
WO2011150284A2 (fr) 2010-05-26 2011-12-01 Baxter International Inc. Élimination de sérine protéases par traitement avec du dioxyde de silicium finement divisé
CA2812643A1 (fr) * 2010-10-13 2012-04-19 Octapharma Ag Methode de purification du facteur h du complement
FR2967071A1 (fr) 2010-11-10 2012-05-11 Lab Francais Du Fractionnement Facteur h pour le traitement de maladies auto-immunes du systeme nerveux
FR2981661B1 (fr) * 2011-10-25 2015-06-19 Lfb Biotechnologies Procede de preparation du facteur h humain
FR2983212A1 (fr) 2011-11-28 2013-05-31 Lfb Biotechnologies Aptameres anti-fh, procede pour leur obtention et utilisations
US9248162B2 (en) 2013-03-14 2016-02-02 Baxalta Incorporated Factor H for treatment of rheumatoid arthritis
HUE039464T2 (hu) 2013-03-14 2019-01-28 Baxalta Inc H-faktor transzplantációra
AU2013202965B2 (en) 2013-03-15 2016-07-21 Takeda Pharmaceutical Company Limited Improved method for producing factor h from a plasma precipitation fraction
AU2013203048A1 (en) 2013-03-15 2014-10-02 Baxalta GmbH Isolation of factor h from fraction i paste
KR102192596B1 (ko) 2013-08-07 2020-12-18 알렉시온 파마슈티칼스, 인코포레이티드 비정형적 용혈성 요독증후군 (ahus) 바이오마커 단백질
IL250667B2 (en) * 2014-08-20 2023-10-01 Stichting Sanquin Bloedvoorziening Factor h potentiating antibodies and uses thereof
KR20220057530A (ko) 2019-07-17 2022-05-09 제미니 테라퓨틱스 서브, 인코포레이티드 인자 h 강화 항체 및 이의 용도
CN113045634B (zh) * 2019-12-28 2023-04-28 四川远大蜀阳药业有限责任公司 一种补体h因子制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0742235B2 (ja) * 1985-11-08 1995-05-10 三共株式会社 自己免疫性疾病の予防・治療剤
GB9624731D0 (en) * 1996-11-28 1997-01-15 Univ Leicester Complement inhibitor
JP2004511492A (ja) * 2000-10-13 2004-04-15 オクタファルマ　アクチェン　ゲゼルシャフト ビクニンを含む血漿画分、その調製方法、およびその使用
EP1336618A1 (fr) * 2002-02-15 2003-08-20 HANS-KNÖLL-INSTITUT FÜR NATURSTOFF-FORSCHUNG e.V. Facteur H du complement de porc et son utilisation
WO2007038995A1 (fr) * 2005-09-19 2007-04-12 Csl Behring Gmbh Facteur h pour le traitement de néphropathies chroniques et sa production

Also Published As

Publication number Publication date
BRPI0619728A2 (pt) 2011-10-11
KR20080091441A (ko) 2008-10-13
CN102988958A (zh) 2013-03-27
JP2012211189A (ja) 2012-11-01
JP2009518368A (ja) 2009-05-07
WO2007066017A2 (fr) 2007-06-14
WO2007066017A3 (fr) 2007-11-08
FR2894145A1 (fr) 2007-06-08
EP1962885A2 (fr) 2008-09-03
CA2633102A1 (fr) 2007-06-14
CN101336111A (zh) 2008-12-31
US20080318841A1 (en) 2008-12-25
AU2006323849A1 (en) 2007-06-14
AU2006323849B2 (en) 2012-11-01
IL191931A0 (en) 2009-02-11

Similar Documents

Publication Publication Date Title
FR2894145B1 (fr) Utilisation de facteur h du complement a titre de medicament
DE602004017510D1 (de) Medizinprodukt vom kapseltyp
DK1907037T4 (da) Lægemiddeldispenser
DK2151438T3 (da) Lægemiddel indeholdende PPAR-Deltaagonist
IL183101A (en) Use of tetrahydrocannabivarin in drug production
BRPI0714539A2 (pt) "formas farmacêuticas"
EP1933936A4 (fr) Enveloppe imprégnée de médicament
DE602005002413D1 (de) Wegwerfhöschen
FR2867064B1 (fr) Doseur de medicaments
IL183929A0 (en) Use of inerferon - ?? in the preparation of a medicament
PT1957073E (pt) Medicamento
FI7535U1 (fi) Saniteettituote
EP1757282A4 (fr) Utilisation de composes de kaurane dans l'elaboration d'un medicament
EP1714648A4 (fr) Medicament de combinaison
FR2920776B1 (fr) Utilisation de derives de purine pour la fabrication d'un medicament
FR2904318B1 (fr) Derives de pyrimidinone et leur utilisation comme medicament
ZA201005396B (en) 17-hydroxy-19-nor-21-carboxylic acid-steroid y-lactone derivative,use thereof,and medicament containing the derivative
ZA200710980B (en) Cripowellins and synthetic derivatives thereof used as medicaments
TWM292546U (en) Medicament counter
FR2907784B1 (fr) Derives phenyliques et leur utilisation comme medicament
UA10109S (uk) Розгортка упаковки лікарського засобу
UA10110S (uk) Розгортка упаковки лікарського засобу
UA10038S (uk) Упаковка фармацевтичного засобу
UA10535S (uk) Упаковка фармацевтичного засобу
UA10054S (uk) Упаковка фармацевтичного засобу

Legal Events

Date Code Title Description
CJ Change in legal form
RM Correction of a material error
ST Notification of lapse

Effective date: 20150831